IMMP News and Press, Immutep Limited From 05/29/23

Media Release Appointment of Charles River Laboratories ("Charles River") to run Immutep’s preclinical toxicology study evaluating the safety and toxicity of IMP761 Forms a key step prior to first-in-human trials for this first-in-class LAG-3 agonist antibody designed to treat ...

2023-05-26 10:29:58 ET Immutep Limited ( NASDAQ: IMMP ) announces that new data has been published from Part C of its TACTI-002 Phase II Trial, evaluating eftilagimod alpha plus pembrolizumab in metastatic 2nd line head and neck squamous cell carcinoma. The mid-stage trial sho...

2023-05-26 08:31:34 ET SunCar Technology Group ( SDA ) -27% . Wearable Devices ( WLDS ) -26% . Tilray Brands ( TLRY ) -22% follows $150M convertible note offering . Nano Labs ( NA ) -16% . Beamr Imaging ( BMR ) -15% . HEXO ( ...

Media Release New data published from Part C of TACTI-002 Phase II Trial evaluating eftilagimod alpha plus pembrolizumab in metastatic 2nd line head and neck squamous cell carcinoma Deep, durable responses seen across all PD-L1 subgroups with a 13.5% Complete Response rate and median ...

Media Release SYDNEY, AUSTRALIA, May 25, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announ...

2023-05-24 12:39:00 ET Are you new to penny stocks? Do you want to know how to use momentum and stock market volatility to your advantage? In many instances, there are hidden opportunities with low-priced stocks, and savvy traders seek to uncover the next big winners. In this article, we wi...

2023-05-24 09:22:54 ET Immutep ( NASDAQ: IMMP ) said its drug eftilagimod alpha plus standard-of-care anti-PD-1 therapy and doublet chemotherapy in first line non-small cell lung cancer (NSCLC) was well tolerated and showed promising initial signals of efficacy in a phase 1 tri...

Media Release Efti plus standard-of-care anti-PD-1 therapy and doublet chemotherapy in 1st line non-small cell lung cancer is well tolerated and continues to show promising initial signals of efficacy Triple combination therapy has achieved a 67% response rate and 91% disease control ...

2023-05-18 16:11:43 ET Summary Immutep’s Efti and Merck's Keytruda combo have shown impressive 25-month median survival rates in Phase 2 trials for NSCLC patients, creating a stir in the biotech sector. Efti, Immutep's lead candidate, boosts the immune response against canc...

2023-05-18 06:00:00 ET Use These Advanced Penny Stocks Techniques to Improve Your Trading Navigating the world of penny stocks comes with its unique set of challenges and rewards. With the right strategies, penny stock trading can potentially be a valuable addition to an investment ...